ASH1L is also an emerging oncogene in acute leukemia (34, 35), thyroid carcinoma (36, 37), prostate cancer (PCa) (38), renal cell carcinoma (39), and hepatoma (40). Here, ASH1L is linked to prostate carcinoma.